Mannkind Corporation (MNKD)
Mannkind Corporation is a biotechnology company focused on discovering, developing, and commercializing inhaled therapeutic products. It is best known for its flagship product, Afrezza, an inhalable insulin used to improve blood sugar control in people with diabetes. The company also develops other inhaled and injectable drug delivery systems aimed at providing innovative solutions for various medical conditions.
Company News
MannKind Corporation announced it will acquire scPharmaceuticals for $303 million, expanding its presence in cardiometabolic and lung diseases. The deal includes an upfront cash payment of $5.35 per share and potential additional milestone payments, representing a 36% premium to scPharmaceuticals' recent trading price.
MannKind reported Q2 2025 revenue of $76.5 million, slightly missing analyst estimates. The company saw growth in Afrezza inhaled insulin sales and Tyvaso DPI royalties, while increasing R&D and marketing expenses.
A Phase 4 study found that more adults with type 1 diabetes achieved target A1C levels when switching from multiple daily injections or insulin pumps to inhaled insulin (Afrezza). The data showed continued improvement in glycemic control for those who remained on Afrezza or switched to it.
MannKind's long-term liabilities exceed its assets, posing potential financial risks. Learn why MNKD stock is a Buy.
MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).